Search Results
May 26, 2026, 09:00 ET Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery
In this episode, Lexogen's CEO shares his perspective on the growing role of RNA sequencing and transcriptomics in enabling AI-driven drug discovery. The discussion highlights how high-quality, dedicated data built with AI training
More news about: LEXOGEN
May 26, 2026, 09:00 ET Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
May 25, 2026, 10:00 ET Levantamento sobre hemofilia revela 'acesso a tratamentos inovadores' como principal necessidade não atendida entre pacientes, cuidadores e profissionais de saúde
para tratar pacientes com hemofilia A ou B com ou sem inibidores do fator VIII ou IX. O tratamento é considerado inovador por utilizar o mecanismo de RNA de interferência para promover o reequilíbrio homeostático, o que permite maior comodidade posológica, oferecendo proteção duradoura e segura, com apenas
More news about: Sanofi
May 25, 2026, 08:45 ET A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
that turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 consists of a messenger RNA encoding an adenine base editor and a guide RNA (gRNA) targeting the PCSK9 gene. Both are encapsulated in a lipid nanoparticle (LNP) and administered as a single intravenous
More news about: Eli Lilly and Company
May 22, 2026, 02:47 ET Gene Solutions 於 TJCC 2026 展示 AI 驅動多體學液態切片創新成果: 推動台灣精準腫瘤醫學發展
驅動整合型平台，該平台結合了多體學數據（基因體、表觀基因體、片段體和轉錄體）與臨床資料，在整個癌症照護旅程中提供可啟發臨床決策的關鍵洞察 —— 從用於多癌種早期檢測（MCED）的 SPOT-MAS，到結合 DNA+RNA 完整分析並搭載 AI 強化工具（如 OriCUP）與融合基因偵測的 K-TRACK 和
More news about: Gene Solutions Genomics Pte., Ltd
May 21, 2026, 10:21 ET Volta Labs führt automatisierte Bibliotheksvorbereitungslösung für das Oxford Nanopore Ligation Sequencing Kit V14 ein
Probenvorbereitung mit dem Callisto™ Sample Prep System. Unter Verwendung der proprietären Electrowetting-Technologie bietet Callisto eine vollautomatische DNA- und RNA-Extraktion und Bibliotheksvorbereitung für alle wichtigen Sequenzierungsplattformen - einschließlich Illumina, Oxford Nanopore, PacBio, Element Biosciences
More news about: Volta Labs
May 21, 2026, 09:05 ET Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14
genomic sample preparation with the Callisto™ Sample Prep System. Using proprietary electrowetting technology, Callisto provides fully automated DNA and RNA extraction and library preparation for all major sequencing platforms — including Illumina, Oxford Nanopore, PacBio, Element Biosciences, and Ultima
More news about: Volta Labs
May 21, 2026, 04:05 ET Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14
genomic sample preparation with the Callisto™ Sample Prep System. Using proprietary electrowetting technology, Callisto provides fully automated DNA and RNA extraction and library preparation for all major sequencing platforms — including Illumina, Oxford Nanopore, PacBio, Element Biosciences, and Ultima
More news about: Volta Labs
May 19, 2026, 22:54 ET Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
May 19, 2026, 17:05 ET Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer
measures endocrine activity in a breast tumor, and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic
More news about: Delphi Diagnostics Inc
May 19, 2026, 11:00 ET The Astros Foundation and Daikin Award $100,000 in Scholarships to Local Students
She has built an impressive early research portfolio through a Rice University internship and projects spanning AI‑based healthcare applications and RNA vaccine development, alongside strong school leadership as a National Honor Society vice president.Marissa Mata – C.E. King High School:
More news about: Daikin Comfort Technologies North America, Inc
May 19, 2026, 10:00 ET Lupus Foundation of America Summer Student Fellowship Program Supports the Future of Lupus Research with Five Grants to Young Scientists
lupus in children.DNA:RNA hybrids in lupus - evaluating the prominence and affinity of autoantibodies to DNA:RNA hybrids (DNA bound to RNA) in people living with lupus which may trigger a more robust immune response than DNA alone. This work may help identify better diagnostic, prognostic
More news about: Lupus Foundation of America, Inc.
May 19, 2026, 09:49 ET Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities,
More news about: Alpha-1 Foundation
May 19, 2026, 09:15 ET Autoimmunity BioSolutions Co-Founder Dr. Mariano A. Garcia-Blanco Inducted into the National Academy of Sciences
recognized leader in RNA biology and RNA virology. He launched his independent scientific career in 1990 as Assistant Professor at Duke University, where he ultimately held the Charles D. Watts Professorship of Molecular Genetics and Microbiology, and founded the Duke Center for RNA Biology.Dr.
More news about: Autoimmunity BioSolutions
May 19, 2026, 09:00 ET Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
May 19, 2026, 08:00 ET etherna's mRNA and LNP Platforms Propel Dropshot Therapeutics' Renal Target to the Clinical Stage
Technologies: Utilizes advanced mRNA chemistry and customizable lipid nanoparticles (cLNPs) to enable the delivery of differentiated and efficacious RNA therapeutics.Strong Foundation: Founded in 2013 as a spin-off from the Vrije Universiteit Brussel (VUB).Global Reach: Headquartered
More news about: etherna
May 18, 2026, 11:45 ET Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research
(Fluorescence-Based Assays, UV-Vis Spectrophotometry, Fluorometric Assays, Colorimetric Assays), By Application (PCR and qPCR, Next-Generation Sequencing (NGS), RNA-Seq and Transcriptomics), By End-Users (Academic and Research Institutions, Biotechnology and Pharmaceutical Companies, Clinical Laboratories), By Geographic
More news about: Verified Market Research
May 18, 2026, 00:18 ET Datar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren
Die FDA-Zulassung unterstreicht die Leistungsfähigkeit von CellDx-Tissue als umfassende DNA- und RNA-basierte Genomprofiling-Lösung zur Analyse von 517 krebsrelevanten Genen einschließlich wichtiger Genfusionen wie ALK, RET und ROS1.NASHIK, Indien,
More news about: Datar Cancer Genetics
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
patentierte Technologie vor, die die Stabilität und Wiederverwendbarkeit von Enzymen erhöht. Sie stellten zwei Fallstudien vor: die Immobilisierung von T7-RNA-Polymerase für halbkontinuierliche In-vitro-Transkriptionssysteme (IVT), bei denen Aktivität und Wiederverwendbarkeit erhalten blieben, sowie die Immobilisierung
More news about: ACROBiosystems Group
May 15, 2026, 10:00 ET Datar Cancer Genetics 的 CellDx-Tissue 獲得美國 FDA 核准，為該項利用 DNA 與 RNA 進行的實體腫瘤全方位基因體分析檢測寫下里程碑
是次核准認定了 CellDx-Tissue 的 DNA 與 RNA 雙分析物工作流程，涵蓋 517 個與癌症相關的基因，並能以 RNA 層級證據偵測 ALK、RET 與 ROS1 等關鍵融合基因印度納西克2026年5月15日 /美通社/ -- 全球精準腫瘤醫學公司 Datar Cancer Genetics (DCG) 今日宣佈，其適用於所有實體腫瘤、以組織為基礎的全方位基因體分析 (comprehensive
More news about: Datar Cancer Genetics
May 15, 2026, 07:06 ET Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
safe peripheral intravenous infusion. (E,E)-bisantrene is a clinical validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent silencing of the important cancer growth regulator MYC.About Racura OncologyRacura Oncology (ASX: RAC)
More news about: Racura Oncology
May 14, 2026, 16:40 ET Atrium Therapeutics Reports First Quarter 2026 Financial Results
May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter
More news about: Atrium Therapeutics
May 14, 2026, 16:13 ET American Society of Gene and Cell Therapy Awards Beverly L. Davidson, PhD, Outstanding Achievement Award
brain, leading to identification of AAVs that more effectively deliver therapeutic cargo to neural tissues.Early development of vectorized RNA interference (RNAi) delivered by AAV, and the first application of this approach to models of neurodegenerative disease.Re‑engineering of AAVs
More news about: Children's Hospital of Philadelphia
May 14, 2026, 16:01 ET Co-Diagnostics Reports First Quarter 2026 Financial Results
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
May 14, 2026, 12:57 ET Hidden small RNA determines if cholera bacterium can infect humans
itself, but a small RNA encoded within it. Variations in this RNA had widespread effects on the expression of genes linked to human infection."We saw that this small RNA is the master regulator of host colonization and infection," Almagro-Moreno said. "Variants in the small RNA from clinical samples
More news about: St. Jude Children's Research Hospital